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ORIGINAL ARTICLEDiagnostic Accuracy of a Short Endoscopic Secretin
Test in Patients With Cystic FibrosisTrond Engjom, MD,*† Friedemann Erchinger, MD,*‡ Birger Norderud Lærum, MD, PhD,§||
Erling Tjora, MD, PhD,||¶ Lage Aksnes, MD, PhD,||¶1
Odd Helge Gilja, MD, PhD,*# and Georg Dimcevski, MD, PhD*†Objective: Short endoscopic secretin tests for exocrine pancreatic func-
tion are not properly evaluated in cystic fibrosis (CF).
Methods: Patients with CF and healthy controls (HCs) underwent endo-
scopic collection of duodenal juice between 30 and 45 minutes after secre-
tin stimulation. Duodenal juice was analyzed for HCO3
− concentration and
pancreatic enzyme activities. Stool was analyzed for fecal elastase.
Results: Thirty-one patients with CF and 25 HCs were tested. Patients
were classified as exocrine pancreatic sufficient (n = 13) or insufficient
(n = 18). Both bicarbonate concentrations and enzyme activities in duode-
nal juice differentiated patients with CFI from patients with CFS and HC
(P < 0.001). The population displays strong correlation between severe CF
genotype in both alleles and pancreatic insufficient phenotype (P < 0.001).
Conclusions: Pancreatic exocrine insufficient CF patients could be dif-
ferentiated from exocrine sufficient patients and HCs using short endo-
scopic secretin test.
Key Words: pancreas, cystic fibrosis, exocrine pancreatic function,
secretin, endoscopy
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C ystic fibrosis (CF) is the most common, fatal autosomal re-cessive disease among white populations, with a frequency
of 1 to 4-5000 live births.1 After the discovery of the CF trans-
membrane regulator (CFTR) gene in 1989 and the linking of the
disease to changes in the CFTR protein,2–4 the CF genotype has
been mapped in details. The CF Mutation Database lists more
than 1900 different mutations in the CFTR gene.5 The CFTR pro-
tein is a complex chloride channel and regulatory protein found
in all exocrine tissues. Various CFTR defects cause disturbed
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pression of disease varies widely as a function of the specific mu-
tations present.6
Pancreatic function testing has played an important role
in the discovery of the mechanism of CF pancreatic pathophys-
iology.6–8 Population studies have indicated that 72% to 88% of
patients with CF develop exocrine pancreatic insufficiency.9,10
Most patients with CF develop insufficiency prenatally or during
first year of infancy.11 Recent studies indicate lower prevalence
of pancreatic insufficiency in CF populations indicating a higher
frequency of milder mutations,9 but still, 87% receives pancreas
enzyme therapy.12 A small proportion of patients with exocrine
pancreatic sufficient CF develop insufficiency later in life,13 lead-
ing to a need for regular follow-up of exocrine pancreatic func-
tion in patients with pancreatic sufficient CF.
Fecal elastase (FE) is the most widespread tool for screening
for exocrine function in patients with CF.13,14 This test is noninva-
sive, cheap, and validated for screening.14 The CF foundation has
published guidelines for pancreatic enzyme substitution based on
FE levels.15 There are, however, some problems using FE. Firstly,
FE has low sensitivity and specificity in detecting mild to moder-
ate pancreatic failure compared with direct testing.16 Secondly,
FE, like all other indirect tests, is unable to assess acinar reserve
capacity or detect ductal dysfunction.17 The test is also affected
by the liquid content in the stool, giving raise to false positives
in patients with watery diarrhea. The pitfalls of FE diagnostics
may reduce the value of such screening in pancreatic sufficient
adults. Some still advocate the use of 3-day fecal fat as the only
option to follow the development toward pancreatic exocrine in-
sufficiency in patients with CF.18
The “criterion standard” direct pancreatic function tests have
good diagnostic accuracy17 but are cumbersome, time consuming,
and technically difficult. These tests have not reached widespread
use and are not suitable as screening tools. New short direct endo-
scopic tests have been evaluated in other pancreatic diseases.19–21
Short endoscopic tests have been criticized for measuring peak
concentrations and not outputs of bicarbonate and digestive en-
zymes. Hence, the validity of such tests in evaluating CF pancre-
atic disease, where hyperconcentration is a part of the mechanism,
has been questioned.17 We aimed to evaluate the diagnostic accu-
racy of our timed short endoscopic secretin test (EST) using FE
as a standard for exocrine failure in a population of patients with
CF with a high prevalence of pancreatic sufficiency and healthy
controls (HCs).
MATERIAL AND METHODS
Subjects
During a 2-year period (December 2010–May 2014), con-
secutive patients with CF older than 15 years attending a regu-
lar follow-up in the CF clinic at Haukeland University Hospital,
Bergen, Norway, were offered a detailed evaluation of exocrine
pancreatic function. Patients with lung-transplanted CF andPancreas • Volume 44, Number 8, November 2015
ealth, Inc. All rights reserved.
FIGURE 1. Inclusion flow chart.
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cluded. Forty-one patients agreed to be included for prospective
data collection. Nine patients did not perform EST. Cystic fibrosis
diagnosis was evaluated according to the diagnostic criteria for
CF defined in the CF foundation consensus report,22 discovering
doubts about the correct CF diagnosis in 3 patients who either had
sweat tests in the area between 40 and 60 mmol/L or lacked exact
information of childhood sweat tests. One patient with intermedi-
ate range sweat test (46 mmol/L) and weak CF phenotypic char-
acteristics was excluded. The other 2 patients had typical CF
phenotype and were included. We thus included 40 patients for
overview of the relation between genotype and exocrine status
and 31 patients with CF for evaluation of EST.
Twenty-six HCs without gastrointestinal disease were also
examined with EST. One HCwas unable to fulfill the EST protocol
and was excluded. Twenty-five HCs were included. The inclusion
flow chart is illustrated in Figure 1. There was an age difference be-
tween the HC and CF groups performing EST as displayed in
Table 1. The protocol was approved by the local ethics committee
(approval number: REK 2010/2857-7) and the studywas performed
in accordance with the Helsinki Declaration. All subjects signed an
informed consent. The protocol adheres to the STARD (STAndards
for the Reporting of Diagnostic accuracy studies) statement.23
Methods
Before the examination medication, smoking habits, alcohol
consumption, and body mass index were documented in allTABLE 1. Results
Patients
CFI (n = 13) C
Age 21 (16–52) 22
Sex, M/F 7/6
Body mass index 21 (16–24) 23
Sweat, Cl− 113 (89–157) 72
F-Elastase, μg/g 0 (0–17) 560
D-Bicarbonate, meq/L 11 (0–24) 118
D-Lipase, 103 U/mL 0 (0–145) 36.0
D-Amylase, U/mL 14.9 (0–99) 281
D-Elastase, U/mL 0 (0–0.24) 0.17
D-Chymotrypsin, U/mL 0 (0–0.22) 3.34
Aspirated volume, mL 1.7 (0–4.9) 6.4
Dry tap n = 3
Results are expressed as medians (range) unless otherwise stated.
CFI/CFS indicates patients with CF with insufficient/sufficient pancreatic fu
ns indicates no significant difference.
© 2015 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2015 Wolters Kluwer subjects. A review of the electronic patient journal was performed,
and information on CFTR mutation and sweat-test values (Na+
and Cl−) were extracted from patient journals as documentation
for the CF diagnosis. The genetic testing was performed over time,
mostly by CF v3 Genotyping kit screening for 33 known CFTR
mutations and collected retrospectively. Additional testing was
performed for the CFTR mutations 4005+2T>C and R117H. Pa-
tients with unconfirmed mutation on screening performed whole
gene sequencing for known CFTR mutations.
Fecal Elastase
Fecal elastase 1 (FE-1) was measured by a commercial
monoclonal analysis kit (ScheBo Biotech, Giessen, Germany).
We classified patients as exocrine pancreatic sufficient or insuffi-
cient by FE-1 concentration. Patients with FE less than 100 μg/g
were considered pancreas insufficient.15
Short Endoscopic Secretin Test
The details of duodenal aspiration, duodenal juice handling,
and analysis are described elsewhere19,20 but will be briefly
described later.
The test procedure is illustrated in Figure 2. All procedures
were performed by 4 experienced operators. Procedures were
performed blinded to knowledge of pancreatic function status.
Blinding to diagnosis and patient appearance was not possible.
The patients received topical pharyngeal lidocaine (XYLOCAIN;
AstraZeneca AB, Sweden) and conscious sedation with intrave-
nous midazolam (MIDAZOLAM; Actavis Group HF, Island) 2
to 5 mg before the procedure. The study participants fasted for
8 hours before Secretin (Secrelux Sanochemia Diagnostics, Neuss,
Germany; 1 CU/kg, maximum dose 70 CU) was administered
intravenously for 1 minute. Twenty-five minutes after secretin ad-
ministration, we performed gastroscopy and carefully emptied the
stomach and duodenum of fluid. Thirty minutes after secretin in-
jection, the tip of the endoscope was placed distal to the papilla
of Vateri and duodenal juice was aspirated through the working
channel of the endoscope in three 5-minute sequences between
30 and 45 minutes after secretin stimulation. The samples were
immediately stored on ice.Controls
FS (n = 18) HC (n = 25) P
(16–70) 38 (19–64) 0.003
8/10 10/15 ns
(19–31) 24 (18–39) ns
(59–89) — <0.001
(169–703) 553 (299–942) <0.001
(54.0–138) 114 (75.0–138) <0.001
(6.90–175) 33.7 (14.1–120) <0.001
(82.9–2200) 297 (89–1727) <0.001
(0.05–0.62) 0.14 (0.03–0.57) <0.001
(0.73–15.0) 2.85 (0.16–7.36) <0.001
(3.00–13.7) 7.5 (3.20–9.90) <0.001
n = 0 n = 0
nction defined by F-elastase cutoff value of 100 μg/g.
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FIGURE 2. The figure displays the examination procedure for EST.
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Each sample was split into 3 aliquots. One aliquot was either
stored on ice for bicarbonate analysis less than 3 hours after col-
lection or snap frozen on liquid nitrogen and stored at less than
80°C until the day of analysis. The other 2 aliquots were snap fro-
zenmore than 5minutes after collection and stored on liquid nitro-
gen until the day of analysis. Before snap freezing, a protease
inhibitor was added to one of these aliquots (Complete; Roche
Diagnostics, Mannheim, Germany; 0.2 mL solution of 1 tablet
per 1.5 mL water added per milliliter duodenal juice).
Duodenal Juice Analysis
Bicarbonate concentration (mEq/L) in duodenal juice was
analyzed by the back titration method24 in each of the 3 samples.
Enzyme activity analyses (U/mL) were performed in 96-well
micro plate assays, using a Tecan Infinite M200 Pro micro-
plate reader with iControl Tecan software (Tecan Group Ltd.,
Mannedorf, Switzerland). We used aliquots treated with protease
inhibitors for activity analyses of pancreas lipase and amylase.
Chymotrypsin and elastase activities were measured in the un-
treated duodenal juice. Samples were diluted as appropriate to
fit into the measuring range for each assay and analyzed in tripli-
cate. We used kinetic, fluorescent assays to determine the activi-
ties of elastase, chymotrypsin, and pancreas lipase. The increase
in relative fluorescence units was measured every 60 seconds after
contact between samples and substrate. We determined activity
by relating the slope of increase in relative fluorescence unit in
the samples to the slopes of enzyme standards. We used a colori-
metric endpoint assay to determine amylase activity. The highest
values of bicarbonate and enzymes were considered to be the peak
level and used as an estimate of exocrine pancreatic function. Pa-
tient with dry tap or low volumes unfit to analyze bicarbonate by
back titration (n = 3) had bicarbonate value defined as zero. The
most widespread cutoff for duodenal bicarbonate concentration
in other pancreatic disease is 80 meq/L.25,26 Others have sug-
gested a cutoff value of 60 mEq/L as a lower limit conservative
cutoff.21 We chose 80 mEq/L in our calculations. Validated cutoff
levels for pancreatic insufficiency based on duodenal concentration/
activities in patients with CF are not established.
Statistical Analysis
All statistics where calculated in SigmaPlot 11, (Copyright
2011 Systat Software Inc., San Jose, Calif ). Normal distribution
of the samples was tested by Kolmogorov-Smirnov test. The
results are expressed as median valueswith range. Simple compar-
isons between groups were made by student t tests or Mann-1268 www.pancreasjournal.com
Copyright © 2015 Wolters Kluwer HWhitney U test when samples were not normally distributed. Re-
ceiver operator curves (ROC curves) were drawn and accuracy data
were calculated. Variance is expressed through 95% confidence in-
tervals. Five percent level of statistical significance was used.
Outliers were not excluded. Patients with missing data in sin-
gle analyses were not excluded. Missing data were not analyzed.
Subjects with missing index analysis (not performed EST) were
excluded from the final diagnostic evaluation.RESULTS
Fecal Elastase
When sorted by results of FE, the patients undergoing EST
were grouped as follows: CF pancreatic insufficient (CFI,
n = 13) and CF pancreatic sufficient (CFS, n = 18). Demographic
data and FE results are displayed in Table 1.
Duodenal Bicarbonate and Enzymes
The values of duodenal bicarbonate concentration and lipase,
amylase, elastase, and chymotrypsin activities are presented in
Table 1 and Figure 3.
Using peak bicarbonate concentrations and peak duodenal
digestive enzyme activity levels, we were able to differentiate the
CFI group from both HCs and CFS patients (P < 0.001). The dif-
ferences between CFS group and HC group were nonsignificant.
Duodenal bicarbonate correlates with volume aspirated in
EST. Duodenal bicarbonate concentration is the most direct CFTR
function measure. If we define an intermediate range of CFTR
function between 60 and 90 mEq/L, we identify 2 patients with
CF in this group. Both these subjects are classified as pancreas
sufficient by the FE cutoff value of 100 μg/g. The plot of bicar-
bonate against lipase activity demonstrates hyperconcentration
of the duodenal enzymes in the 2 patients with CF in the inter-
mediate bicarbonate level (Fig. 4).
Diagnostic Accuracy
Receiver operator curves were calculated for bicarbonate
concentrations and enzyme activities. Sensitivity and specific-
ity corresponded to suggested cutoff values are displayed in
Table 2. Compared with FE as standard for exocrine function,
D-bicarbonate has a sensitivity of 100% and a specificity of 88%
with the usual cutoff value set to 80 meq/L (P < 0.001). The pos-
itive predictive value of the test was 91% and the negative pre-
dictive value was 100% compared with the same standard. D
enzymes have slightly lower sensitivities and specificities com-
pared with the FE standard, but the differences in ROC areas
between enzymes and bicarbonate are nonsignificant (Table 2).
Genotype/Phenotype Analysis
A list of known mutations organized according to pancreatic
phenotype for the whole group (n = 40) is displayed in Table 3.
There is a strong tendency toward pancreatic insufficient pheno-
type in the group with known, severe CFmutations on both alleles
(P < 0.001). The group with pancreatic sufficient phenotype has
the highest number of patients without a known CF mutation.
As noted earlier, the quality review of the CF diagnosis is accord-
ing to diagnostic criteria,22 discovering doubts about the correct
CF diagnosis in 3 patients (one excluded). Neither of these patient
had pancreatic insufficient phenotype. One patient had a patho-
genic mutation in one of the CFTR alleles; the other two had no
known CFTR mutation.© 2015 Wolters Kluwer Health, Inc. All rights reserved.
ealth, Inc. All rights reserved.
FIGURE 3. Box and scatter plots for peak bicarbonate concentrations and peak duodenal pancreatic enzyme activities divided by groups.
Pancreas • Volume 44, Number 8, November 2015 A Short Endoscopic Secretin Test in CFAdverse Events
The subjects reported mild abdominal discomfort and sensa-
tion of hunger connected to the secretin infusion. Most subjects
also reported mild to moderate discomfort during the endoscopy.
Heart rhythm, pulse, and oxygen saturation were observed in all
subjects during the procedure. No complications or severe adverse
events were reported.FIGURE 4. The figure illustrates the correlation between peak
duodenal bicarbonate concentration and duodenal lipase activity
in the patients with CF. Mark especially the 2 patients with
intermediate bicarbonate concentrations, aspirated volumes in
the lower normal range and hyperconcentrated duodenal enzymes.
White circles indicates CFI; black circles, CFS.DISCUSSION
In the present study, we demonstrate that a new, short EST
is well tolerated and has a good diagnostic accuracy in assess-
ing exocrine pancreatic function in patients with CF. We demon-
strated a good correspondence between duodenal bicarbonate
after secretin stimulation and the FE standards in the pancreas in-
sufficient patients. Furthermore, duodenal enzyme concentrations
also had fair correspondence with FE in both the pancreas suffi-
cient groups and the patients with severe insufficiency. Among
patients with CF with intermediate bicarbonate levels, we discov-
ered 2 patients with CF with marked elevated pancreatic enzyme
activity levels in all enzyme groups compared with other patients
and controls. This phenomenon might prove to be a marker to
identify patients with pancreatic sufficient CF at risk of or in the
process of developing pancreatic insufficiency. Exocrine pancre-
atic test results were well correlated to the severity of CF geno-
type in our population.
Fecal elastase has previously demonstrated to be an excellent
tool in repeated evaluation of exocrine pancreatic function in
patients with CF and has more or less prevented the need for
more complex, direct pancreatic function tests.11,14,27 However,
FE has demonstrated weaknesses compared with the secretin-
cholecystokinin test when aiming to follow progress in pancreatic© 2015 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2015 Wolters Kluwer failure or to detect early failure.16 Fecal elastase is not a tool to
directly assess pancreatic ductal function.17 Development of the
new, expensive CFTR modulators28 will increase the need of a
clinical test to evaluate pancreatic CFTR function. Evaluation of
the new, timed ESTs19–21,29 has to our knowledge previously not
been performed in patients with CF. Schibli et al17 stated that tests
with short sampling periods, concentration-based end points, andwww.pancreasjournal.com 1269
Health, Inc. All rights reserved.
TABLE 3. CFTR Mutations
Combinations of Known CF Mutation Related to Exocrine
Pancreatic Function
CFI (n = 19) CFS (n = 21)
ΔF508/ΔF508 (n = 10) ΔF508/R117H (n = 1)
ΔF508/S912x (n = 3) ΔF508/V232D (n = 1)
ΔF508/E60X (n = 1) ΔF508/4005+2T>C (n = 2)*
ΔF508/G542x (n = 1) ΔF508/3849+10kbc>T (n = 1)*
ΔF508/1525-SA->G (n = 1) G551D/75Q (n = 1)
621+1G>T/4005+2T>C (n = 1) ΔF508/- (n = 1)
394delTT/S912x (n = 1) 1525-47T->G/- (n = 1)
R1162x/1525-2A>G (n = 1) R117H/- (n = 2)
No mutation found (n = 0) No mutation found (n = 11)
Overview of known mutation related to pancreatic phenotype.
*Patients with subnormal D-bicarbonate and enzyme hyperconcentration.
TABLE 2. Test Accuracy
Sensitivity (95% CI) Specificity (95% CI) Cutoff AUC
D-Bicarbonate 1 (0.74–1) 0.88 (0.75–0.96) 80 meq/L 1
D-Lipase 1 (0.71–1) 0.92 (0.79–0.98) 15,000 U/mL 0.99
D-Amylase 1 (0.72–1) 0.93 (0.80–0.98) 100 U/mL 0.99
D-Elastase 1 (0.69–1) 0.95 (0.83–0.99) 0.05 U/mL 1
D-Chymotrypsin 1 (0.72–1) 0.90 (0.76–0.97) 1 U/mL 1
Diagnostic accuracy calculated from ROC curves for the CF group. Regarding duodenal bicarbonate, the cutoff is established in earlier studies. Regard-
ing duodenal enzymes, the suggested cutoff values are extracted from our ROC calculations.
AUC, area under the curve calculated from ROC curves.
Engjom et al Pancreas • Volume 44, Number 8, November 2015lacking evaluation of intestinal losses could create considerable
errors when estimating pancreatic function in patients with CF, es-
pecially in the intermediate range. However, the short period ana-
lyzed in their study was confined to samples collected during the
first 20 minutes after secretin stimulation, which later has been
shown to be before the peak bicarbonate level in the duodenum
in other studies including chronic pancreatitis patients.25,29 We
claim that bicarbonate-concentration measure in duodenal juice
is a physiological correct way to assess failure in CFTR function,
because ductal secretion of water and bicarbonate is dependent of
CFTR.8 Challenges in timing of duodenal collection and pollution
from gastric ventricular fluid with low pH have been addressed
in earlier works validating ESTs.21,30 The complex tube-based
tests probably have better accuracy than shorter, concentration-
based tests and should still be considered as criterion standard,
but the fact that these tests have existed for decades without
achieving widespread use justifies the search for simplified
methods. We believe that our timed protocol can achieve accept-
able results comparable with the more cumbersome and complex
direct tests and that EST can prove to be a valuable direct CFTR-
function test. To make a final conclusion on this issue, an evalua-
tion of the FE and EST against the old quantitative direct tests
must be conducted.
We chose FE as a standard for exocrine pancreatic function
in our protocol because this is the simplest and most widespread
test; thus, the protocolwas not designed to compare the diagnostic
accuracies of EST and FE. The conservative FE cutoff value of
100 μg/g gives a firm definition for the pancreas insufficient
group. The influence of the possible low sensitivity in the FE test
of early exocrine failure cannot be decided and specificity levels
achieved for EST are influenced from reduced sensitivity of FE.
Another accepted criterion standard for exocrine function in CF
is the 3-day fecal-fat sample. Because of the lack of sensitivity
of this test for mild to moderate failure, this standard will suffer
from the same pitfalls as FE.
Analyses of pancreatic enzymes infer numerous practical pit-
falls and require conscious handling of the duodenal samples.20
These analyses demonstrate lower diagnostic accuracy compared
with bicarbonate. Still, we propose that pancreatic enzyme activity
assessment gives valuable, additional information. Firstly, our
procedure for analyzing duodenal enzymes requires only small
amounts of fluid; thus, we are able perform analyses in patients
with CFwith severe volume output failure. Secondly, the phenom-
enon of enzyme hyperconcentration illustrates an etiological fac-
tor postulated to pre-exist the pancreatic destruction in CF. This
may prove to be a sign of early volume output failure.
The correlation between CF genotype and pancreatic insuffi-
cient phenotype is well established in several studies.31–33 In the
present study, the information on genotype was collected retro-
spectively from a patient registry, and the tests were performed1270 www.pancreasjournal.com
Copyright © 2015 Wolters Kluwer Hfor a period. The population has a number of unidentified CF
mutations in the CFS group. Patients with CF in western Norway
are earlier described to have a low prevalence of pancreatic insuf-
ficiency, possibly due to regional variations in genotype with a
higher prevalence of milder CF mutations.34 We did not include
patients with lung transplants or severe lung disease. Thus, the
population presented is not a representative cohort of the whole
CF population in our region. It is still interesting to note that also
in our population, patients with CF with severe CF genotype have
a high rate of exocrine pancreatic insufficiency and those milder
mutations or unknown mutation status is a predictor pancreatic
sufficiency; thus, the EST results fit the expectations when corre-
lated to genotype.
We find all of the patients with CF-related disorder or doubt-
ful CF diagnosis in the CFS group. We excluded one but chose to
include the 2 others because of the presence of significant clinical
signs of CF phenotype represented by classical organ manifesta-
tions and colonization from CF-associated pathogens strongly
suggestive of CF. As noted by Ooi et al,35 the diagnostic guide-
lines provide guidance and promote rigorous evaluation for the di-
agnosis of CF but neither guideline should be regarded as dogma.
The genetic diversity combined with a remaining uncertainty of
the diagnosis in the CFS group may explain why we are not able
to identify reduced bicarbonate levels in this group compared with
HCs. Whether the presence of milder or heterozygote CFTR muta-
tion can give partly reduced CFTR function and reduced duodenal
bicarbonate compared with subjects with normal CFTR status re-
mains unanswered.© 2015 Wolters Kluwer Health, Inc. All rights reserved.
ealth, Inc. All rights reserved.
Pancreas • Volume 44, Number 8, November 2015 A Short Endoscopic Secretin Test in CFIn the present study, we aimed to evaluate our short EST in
a group of patients with CF with a well-established clinical diag-
nosis. Despite the fact that EST is an invasive test, the current ver-
sion using less than 20-minute sampling time is feasible and can
be performed in patients with CFwith a low risk of patient hazard.
Our study is the first evaluation of a timed short EST in patients
with CF compared with HCs. Because of costs, test simplicity,
and lack of patient hazard, FE will remain the first choice for
assessing exocrine pancreatic function in patients with CF. We
believe that the EST can be a valuable clinical supplement where
the FE result leaves doubt whether there is pancreatic insuffi-
ciency or not. Particularly, the test might prove useful in selected
patients with CF at risk if a combination of bicarbonate and en-
zyme values can give an indication on early or forthcoming exo-
crine pancreatic insufficiency. Whether the test can identify early
or the risk of future pancreatic insufficiency remains unanswered.
The effect of enzyme hyperconcentration in the phase of early
pancreatic failure needs further confirmation in a protocol with
a higher number of patients in this phase of disease progression.
An important near-future perspective can be to identify subjects
to be targeted for therapeutic interventions with new CFTR mod-
ulators to preserve pancreatic function.
ACKNOWLEDGMENTS
The authors give their special acknowledgement to the
supporting laboratory technicians Liv Aasmul and Aud Sissel
Hjartholm for preserving and running analyses on duodenal juice
and to Line Lærum for always keeping the spirit up in the at-
tending patients with CF.
REFERENCES
1. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373:
1891–1904.
2. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic
fibrosis gene: genetic analysis. Science. 1989;245:1073–1080.
3. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic
fibrosis gene: cloning and characterization of complementary DNA.
Science. 1989;245:1066–1073.
4. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic
fibrosis gene: chromosome walking and jumping. Science. 1989;245:
1059–1065.
5. Cystic fibrosis genetic analysis consortioum. CF Mutation Database.
[Database Online]. Available at: http://www.genet.sickkids.on.ca/app.
Accessed May 9, 2014.
6. Wilschanski M, Durie PR. Patterns of GI disease in adulthood associated
with mutations in the CFTR gene. Gut. 2007;56:1153–1163.
7. Kopelman H, Durie P, Gaskin K, et al. Pancreatic fluid secretion and
protein hyperconcentration in cystic fibrosis. N Engl J Med. 1985;
312:329–334.
8. Kopelman H, Corey M, Gaskin K, et al. Impaired chloride secretion,
as well as bicarbonate secretion, underlies the fluid secretory defect in the
cystic fibrosis pancreas. Gastroenterology. 1988;95:349–355.
9. Augarten A, Ben Tov A,Madgar I, et al. The changing face of the exocrine
pancreas in cystic fibrosis: the correlation between pancreatic status,
pancreatitis and cystic fibrosis genotype. Eur J Gastroenterol Hepatol.
2008;20:164–168.
10. Borowitz D, Baker SS, Duffy L, et al. Use of fecal elastase-1 to classify
pancreatic status in patients with cystic fibrosis. J Pediatr. 2004;145:
322–326.
11. O'Sullivan BP, Baker D, Leung KG, et al. Evolution of pancreatic function
during the first year in infants with cystic fibrosis. J Pediatr. 2013;162:
808–812.© 2015 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2015 Wolters Kluwer 12. Cystic Fibrosis Foundation Patient Registry. 2012 Annual data report.
Available at: http://www.cff.org/UploadedFiles/aboutCFFoundation/
AnnualReport/2012-Annual-Report.pdf. Accessed May 9, 2014.
13. Couper RT, Corey M, Moore DJ, et al. Decline of exocrine pancreatic
function in cystic fibrosis patients with pancreatic sufficiency. Pediatr Res.
1992;32:179–182.
14. Walkowiak J, Nousia-Arvanitakis S, Agguridaki C, et al. Longitudinal
follow-up of exocrine pancreatic function in pancreatic sufficient cystic
fibrosis patients using the fecal elastase-1 test. J Pediatr Gastroenterol
Nutr. 2003;36:474–478.
15. Borowitz D, Robinson KA, RosenfeldM, et al. Cystic Fibrosis Foundation
evidence-based guidelines for management of infants with cystic fibrosis.
J Pediatr. 2009;155:S73–S93.
16. Walkowiak J, Cichy WK, Herzig KH. Comparison of fecal elastase-1
determination with the secretin-cholecystokinin test in patients with
cystic fibrosis. Scand J Gastroenterol. 1999;34:202–207.
17. Schibli S, Corey M, Gaskin KJ, et al. Towards the ideal
quantitative pancreatic function test: analysis of test variables that
influence validity. Clin Gastroenterol Hepatol. 2006;4:
90–97.
18. Weintraub A, Blau H, Mussaffi H, et al. Exocrine pancreatic function
testing in patients with cystic fibrosis and pancreatic sufficiency: a
correlation study. J Pediatr Gastroenterol Nutr. 2009;48:306–310.
19. Erchinger F, Engjom T, Tjora E, et al. Quantification of pancreatic function
using a clinically feasible short endoscopic secretin test. Pancreas.
2013;42:1101–1106.
20. Tjora E, Wathle G, Engjom T, et al. Severe pancreatic dysfunction
but compensated nutritional status in monogenic pancreatic disease
caused by carboxyl-ester lipase mutations. Pancreas. 2013;42:
1078–1084.
21. Jensen NM, Larsen S. A rapid, endoscopic exocrine pancreatic function
test and the Lundh test: a comparative study. Pancreatology. 2008;8:
617–624.
22. Farrell PM, Rosenstein BJ, White TB, et al. Guidelines for diagnosis
of cystic fibrosis in newborns through older adults: Cystic Fibrosis
Foundation consensus report. J Pediatr. 2008;153:S4–S14.
23. STARD. Statement Standards for the Reporting of Diagnostic accuracy
studies. Available at: http://www.stard-statement.org/. Accessed
May 9, 2014.
24. Segel IH. Acid-Base chemistry. In: Segel IH, ed. Biochemical Calculations.
2nd ed. New York: Wiley; 1976:1–91.
25. Conwell DL, Zuccaro G Jr, Vargo JJ, et al. An endoscopic pancreatic
function test with synthetic porcine secretin for the evaluation of chronic
abdominal pain and suspected chronic pancreatitis. Gastrointest Endosc.
2003;57:37–40.
26. Stevens T, Conwell DL, Zuccaro G Jr, et al. A prospective crossover study
comparing secretin-stimulated endoscopic and Dreiling tube pancreatic
function testing in patients evaluated for chronic pancreatitis. Gastrointest
Endosc. 2008;67:458–466.
27. Walkowiak J, Sands D, Nowakowska A, et al. Early decline of pancreatic
function in cystic fibrosis patients with class 1 or 2 CFTR mutations.
J Pediatr Gastroenterol Nutr. 2005;40:199–201.
28. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in
patients with cystic fibrosis and the G551D mutation. N Engl J Med.
2011;365:1663–1672.
29. Stevens T, Conwell DL, Zuccaro G Jr, et al. The efficiency of endoscopic
pancreatic function testing is optimized using duodenal aspirates at
30 and 45 minutes after intravenous secretin. Am J Gastroenterol. 2007;
102:297–301.
30. Stevens T, Conwell DL, Zuccaro G Jr, et al. A randomized crossover
study of secretin-stimulated endoscopic and dreiling tube pancreaticwww.pancreasjournal.com 1271
Health, Inc. All rights reserved.
Engjom et al Pancreas • Volume 44, Number 8, November 2015function test methods in healthy subjects. Am J Gastroenterol. 2006;101:
351–355.
31. Ahmed N, Corey M, Forstner G, et al. Molecular consequences of
cystic fibrosis transmembrane regulator (CFTR) gene mutations in the
exocrine pancreas. Gut. 2003;52:1159–1164.
32. Durno C, Corey M, Zielenski J, et al. Genotype and
phenotype correlations in patients with cystic fibrosis and
pancreatitis. Gastroenterology. 2002;123:
1857–1864.1272 www.pancreasjournal.com
Copyright © 2015 Wolters Kluwer H33. Ooi CY, Dorfman R, Cipolli M, et al. Type of CFTR mutation
determines risk of pancreatitis in patients with cystic fibrosis.
Gastroenterology. 2011;140:153–161.
34. Dorlöchter L, Aksnes L, Fluge G. Faecal elastase-1 and fat-soluble
vitamin profiles in patients with cystic fibrosis in Western Norway.
Eur J Nutr. 2002;41:148–152.
35. Ooi CY, Dupuis A, Ellis L, et al. Comparing the American and
European diagnostic guidelines for cystic fibrosis: same disease,
different language? Thorax. 2012;67:618–624.© 2015 Wolters Kluwer Health, Inc. All rights reserved.
ealth, Inc. All rights reserved.
